logo

Bicycle Therapeutics (BCYC)



Trade BCYC now with
  Date
  Headline
3/30/2021 7:10:28 AM Bicycle Therapeutics Announces Progress Updates For Bicycle-based Partnered Programs Outside Of Oncology
3/18/2021 8:37:18 AM Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos To Its Board
3/11/2021 7:22:46 AM Bicycle Therapeutics Q4 Net Loss $17.4 Mln Or $0.83/Shr Vs Loss Of $4.4 Mln Or $0.25/Shr Last Year
1/14/2021 7:12:35 AM Bicycle Therapeutics Says Start 2021 By Announcing Clinical Progress Across Internal Oncology Pipeline
11/5/2020 7:51:49 AM Bicycle Therapeutics Q3 Net Loss $10.1 Mln Or $0.52/shr Vs Net Loss $9.5 Mln Or $0.53/shr Last Year
9/2/2020 7:05:10 AM Bicycle Therapeutics Says First Patient Dosed In Phase IIa Trial Of Bicycle Toxin Conjugate BT1718
9/1/2020 7:12:40 AM Bicycle Therapeutics Announces First Patient Dosed In Oxurion's Phase II Study Of THR-149
8/11/2020 7:04:21 AM Bicycle Therapeutics Appoints Dominic Smethurst As Chief Medical Officer
8/5/2020 7:18:40 AM Bicycle Therapeutics Q2 Loss/shr $0.67 Vs. Loss/shr $1.40 Last Year
6/23/2020 7:02:19 AM Bicycle Therapeutics Appoints Keith Peters As Chairman Of Scientific Advisory
6/22/2020 7:19:33 AM Bicycle Therapeutics Presents New Translational Data For BT5528 And Preclinical Data For TICAs At AACR
5/5/2020 7:13:54 AM Bicycle Therapeutics Says First Patient Dosed In Phase I Dose Escalation Of BT5528 In Combination With Nivolumab
3/10/2020 7:03:34 AM Bicycle Therapeutics Q4 Loss Per Share $0.25 Vs Loss $13.19 Last Year
2/25/2020 7:13:40 AM Bicycle Therapeutics Enters Strategic Collaboration With Genentech To Develop Bicycle(r)-based Immuno-oncology Therapies
11/13/2019 7:03:16 AM Bicycle Therapeutics Announces First Patient Dosed In Phase I/II Trial Of Bicycle(r) Toxin Conjugate BT5528
10/22/2019 3:08:08 AM Bicycle Therapeutics Says Expands Neuroscience Collaborations To Include Oxford Drug Discovery Institute
9/24/2019 7:08:11 AM Bicycle Therapeutics To Present Updated Data From Phase I/IIa Trial Of BT1718 At ESMO 2019 Annual Congress